At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CURE Direxion Daily Healthcare Bull 3X Shares
Pre-Mkt 07-23 08:05:31 EDT
112.13
-1.99
-1.74%
盘前112.12
-0.01-0.01%
04:00 EDT
High115.59Low111.40Vol44.26K
Open115.59D1 Closing114.12Amplitude3.68%
Mkt Cap168.20MTradable Cap168.20MTotal Shares1.50M
T/O4.97MT/O Rate2.95%Tradable Shares1.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Eli Lilly notes retatrutide met primary endpoint in TRIUMPH-2, TRIUMPH-3 trials
TIPRANKS  ·  18:55
Eli Lilly notes retatrutide met primary endpoint in TRIUMPH-2, TRIUMPH-3 trials
Lilly Targets Q1 2027 FDA Filing for Retatrutide Obesity Approval
Reuters  ·  18:46
Lilly Targets Q1 2027 FDA Filing for Retatrutide Obesity Approval
Eli Lilly Issues Press Release on Retatrutide Phase 3 Obesity Trial Results
Reuters  ·  18:46
Eli Lilly Issues Press Release on Retatrutide Phase 3 Obesity Trial Results
Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1c
THOMSON REUTERS  ·  18:45
Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1c
Eli Lilly: in Triumph-3, Adults with Severe Obesity & Established Cardiovascular Disease Lost up to Average of 55.8 Lbs (22.6%) at 80 Weeks
THOMSON REUTERS  ·  18:45
Eli Lilly: in Triumph-3, Adults with Severe Obesity & Established Cardiovascular Disease Lost up to Average of 55.8 Lbs (22.6%) at 80 Weeks
Eli Lilly: Plans to Submit Biologics License Application for Retatrutide to FDA in Q1 2027
THOMSON REUTERS  ·  18:45
Eli Lilly: Plans to Submit Biologics License Application for Retatrutide to FDA in Q1 2027
India's Cipla Posts Another Profit Decline, Names Insider Dinesh Jain CFO
Reuters  ·  15:02
India's Cipla Posts Another Profit Decline, Names Insider Dinesh Jain CFO
Ascletis Announces Oral Discussion of Asc36_35 Fdc Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/tirzepatide Combination at the 62nd European Association for the Study of Diabetes (easd) Annual Meeting
THOMSON REUTERS  ·  08:10
Ascletis Announces Oral Discussion of Asc36_35 Fdc Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/tirzepatide Combination at the 62nd European Association for the Study of Diabetes (easd) Annual Meeting
Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors
Dow Jones  ·  04:32
Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors
Eli Lilly Updates Financial Calendar with Quarterly Results Conference Call
Reuters  ·  07-22 22:01
Eli Lilly Updates Financial Calendar with Quarterly Results Conference Call
PRESS Digest-british Business - July 22
Reuters  ·  07-22 10:24
PRESS Digest-british Business - July 22
PRESS Digest-financial Times - July 22
Reuters  ·  07-22 09:53
PRESS Digest-financial Times - July 22
Sector Update: Healthcare
MT Newswires Live  ·  07-22 00:59
Sector Update: Healthcare
Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising
MT Newswires Live  ·  07-21 23:49
Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising
Eli Lilly: Rather than Compete on the Merits of Its Products, Novo is Asking Court to Stop Lilly from Communicating Results of That Trial
THOMSON REUTERS  ·  07-21 22:42
Eli Lilly: Rather than Compete on the Merits of Its Products, Novo is Asking Court to Stop Lilly from Communicating Results of That Trial
Eli Lilly on Novo Nordisk Lawsuit- "we Stand Firmly Behind Our Advertising"
THOMSON REUTERS  ·  07-21 22:42
Eli Lilly on Novo Nordisk Lawsuit- "we Stand Firmly Behind Our Advertising"
Eli Lilly: We Will Continue to Focus on the Science and Defend Against Novo Nordisk Lawsuit Vigorously
THOMSON REUTERS  ·  07-21 22:42
Eli Lilly: We Will Continue to Focus on the Science and Defend Against Novo Nordisk Lawsuit Vigorously
U.S. Stocks on the Move-utz Brands, Tutor Perini, Tripadvisor
Reuters  ·  07-21 21:27
U.S. Stocks on the Move-utz Brands, Tutor Perini, Tripadvisor
Novo Nordisk Says Mismatched Diabetes Drug Ads Triggered Lawsuit Vs. Lilly
Dow Jones  ·  07-21 20:23
Novo Nordisk Says Mismatched Diabetes Drug Ads Triggered Lawsuit Vs. Lilly
Novo Sues Lilly, Claiming Misleading Ads in Weight-loss Drug Battle
Reuters  ·  07-21 20:00
Novo Sues Lilly, Claiming Misleading Ads in Weight-loss Drug Battle

Introduction

Company Name.
Direxion Daily Healthcare Bull 3X Shares
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified.
Issue price:
--